The National Health Insurance Authority (NHIA) is set to commence local production of NHIA-branded medications through a strategic partnership with pharmaceutical companies, a move aimed at improving access to quality drugs and strengthening trust in the national health insurance scheme.
Disclosing this development in Ibadan during an interview with the News Agency of Nigeria (NAN), Oyo State NHIA Coordinator, Mr. Babajide Daramola, stated that the initiative forms part of broader reforms to enhance healthcare delivery and reposition the NHIA for improved public perception.
“To ensure the consistent availability of quality medications for our enrollees, we have entered agreements with pharmaceutical manufacturers to produce NHIA-branded drugs. These will be distributed across all NHIA-accredited health facilities nationwide,” Daramola said.
He confirmed that a Memorandum of Understanding (MoU) had been signed with implementation expected to commence before the end of the year.
Daramola further encouraged enrollees to actively report challenges encountered at healthcare facilities, particularly regarding drug availability and quality. “We urge enrollees to provide timely feedback. When cases of poor drug quality or out-of-pocket purchases are reported, we investigate and reimburse where necessary,” he assured.
The NHIA, he noted, remains committed to quality assurance through regular facility audits and enforcement of compliance among service providers. While acknowledging that some complaints have proven unfounded, he emphasized that every report is treated with due diligence.
Clarifying the scheme’s medication policy, Daramola explained that the NHIA—like health insurance programmes globally—primarily relies on generic drugs, which are chemically equivalent and therapeutically effective alternatives to branded versions. “This is a standard practice in health systems worldwide, including in countries like the UK, USA, and Germany,” he added.
Despite the initiative, some enrollees have continued to raise concerns over recurring drug shortages and quality issues. Esther Adedeji, a beneficiary at the NHIA pharmacy in University College Hospital (UCH), Ibadan, noted the unavailability of prescribed medications. “I’ve had to purchase drugs outside at higher prices due to frequent stockouts,” she said.
Another enrollee, Anthony Yusuf, expressed dissatisfaction with the quality and coverage of medications provided. “We often receive subpar drugs, and sometimes we’re told our NHIA or HMO plan doesn’t cover certain treatments,” he claimed.
Similarly, Francis Ogunsola highlighted the inconsistent supply of drugs. “There are days when the pharmacy has everything, and other times when key medications are missing,” he noted.
Responding to these concerns, Dr. Happy Adedapo, Chairman of the Oyo State chapter of the Nigerian Medical Association (NMA), attributed the drug supply challenges to irregular funding and the escalating cost of pharmaceuticals. He urged the government to increase financial support for the NHIA and implement effective oversight mechanisms.
“Policy implementation must go beyond rhetoric. For the healthcare system to improve, funding must be consistent, and accountability must be enforced,” Adedapo stressed.
He further emphasized the broader implications of a dysfunctional health system, noting that the continued exodus of public officials seeking treatment abroad is symptomatic of deep-rooted challenges in Nigeria’s healthcare infrastructure.
“A coordinated effort by the government, insurance administrators, and private stakeholders is essential to restoring credibility and functionality to our healthcare delivery system,” he added.
